Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)-Reference-Cited by-同舟云学术

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)

Published:2016-10-11 Issue:4 Volume:44 Page:355-362
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Saeki Hidehisa¹,Nakagawa Hidemi²,Nakajo Ko³,Ishii Taeko³,Morisaki Yoji³,Aoki Takehiro³,Cameron Gregory S.⁴,Osuntokun Olawale O.⁴,

Affiliation:

1. Department of Dermatology; Nippon Medical School; Tokyo Japan

2. Department of Dermatology; The Jikei University School of Medicine; Tokyo Japan

3. Lilly Research Laboratories; Eli Lilly Japan K.K.; Kobe Japan

4. Lilly Research Laboratories; Eli Lilly and Company; Indianapolis Indiana USA

Funder

Eli Lilly Japan K.K. ProScribe's services

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1346-8138.13622/fullpdf

Reference19 articles.

1. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database;Kubota;BMJ Open,2015

2. Targeting of interleukin-17 in the treatment of psoriasis;Lonnberg;Clin Cosmet Investig Dermatol,2014

3. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis;Leonardi;N Engl J Med,2012

4. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis;Gordon;J Am Acad Dermatol,2014

5. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials;Griffiths;Lancet,2015

Cited by 169 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies;Expert Opinion on Drug Safety;2024-09-12

2. A case of eczematous paradoxical reactions on the extremities during tildrakizumab treatment for plaque psoriasis;The Journal of Dermatology;2024-09-04

3. Biologic anti-IL17 drugs in erythrodermic psoriasis;JAAD International;2024-09

4. Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis;Expert Opinion on Drug Safety;2024-08-17

5. Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search;Dermatology and Therapy;2024-08-01